Development DelaysThe company will hold off on its clinical trial initiation in order to further develop its system to be 'product ready', indicating a pause until further notice.
Financial ChallengesRBOT's capital position remains its biggest challenge as RBOT exited 2Q25 with ~$24.0M in cash and continues to expect ~$50M in cash burn for FY25 forcing RBOT to make some tough decisions.
Strategy ShiftThe shift in strategy means delaying the treatment of the first clinical patients, prioritizing finalizing a production-equivalent system instead.